Cystic fibrosis transmembrane conductance regulator (CFTR) triple modulator therapy, elexacaftor–tezacaftor–ivacaftor (ETI) has transformed care for people with cystic fibrosis (CF) who have eligible mutations. This evidence concerns the gene CFTR and cystic fibrosis.